DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Circulating Tumor Cell, Cell Free DNA, Exosome and Vesicle Cancer Diagnostic Markets 2016 including Screening Market - Potential Sizing" report to their offering.
The Diagnostic, Monitoring and Screening Test opportunities are explored.
A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology creates new markets for cancer screening tests.
GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has outstanding growth potential. The impact on the health care industry is enormous. The report forecasts the market size out to 2020. In addition, the report looks at potential market sizes by country, by cancer and by the three different opportunities: detection, management and screening.
Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.
The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate and Other Cancers.
Key Topics Covered:
1. Introduction and Market Definition
2. Market Overview
3. Market Trends
4. Liquid Biopsy Recent Developments
5. Country Market Sizes - North America
6. Country Markets - Europe
7. Country Markets - Asia Pacific
8. Country Markets - Latin America, Africa & The Middle East
9. Global Market Summary
10. Potential Market Opportunity Sizes
I. United States Medicare System: January 2015 Clinical Laboratory Fees Schedule - National Limit and Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Pharmacogenomics Tests
- AdnaGen (now Qiagen)
- Agena Bioscience
- Angle plc
- Cancer Genetics, Inc.
- Chronix Biomedical
- Epic Sciences
- Exosome Diagnostics
- Exosome Sciences
- Fluidigm Corp
- Fluxion Biosciences
- GATC Biotech
- Genomic Health
- Guardant Health
- HTG Molecular
- Molecular MD
- Myriad Genetics
- New Oncology
- Pathway Genomics
- Personal Genome Diagnostics
- RainDance Technologies
- Rarecells SAS
- Resolution Bio
For more information about this report visit http://www.researchandmarkets.com/research/zs4vsj/circulating_tumor